| Field Name                        | Field Description  |
|-----------------------------------|--|
| Prior Authorization               | Rytelo   |
| Group Description                 |  |
| Drugs                             | Rytelo (imetelstat)  |
| Covered Uses                      | Medically accepted indications are defined using the following<br>sources: the Food and Drug Administration (FDA), Micromedex,<br>American Hospital Formulary Service (AHFS), United States<br>Pharmacopeia Drug Information for the Healthcare Professional<br>(USP DI), the Drug Package Insert (PPI), or disease state specific<br>standard of care guidelines.   |
| Exclusion Criteria                | N/A  |
| Required Medical<br>Information   | See "Other Criteria"   |
| Age Restrictions                  | Member must be 18 years of age and older   |
| Prescriber<br>Restrictions        | Prescriber must be a hematologist or oncologist  |
| Coverage Duration                 | If all of the criteria are met, the initial request will be approved for 6 months. For continuation of therapy, the request will be approved for 6 months.   |
| Other Criteria                    | Initial Authorization:   |
|                                   | <ul> <li>Diagnosis of myelodysplastic syndromes (MDS) with transfusion-dependent anemia</li> <li>Myelodysplastic Syndrome Revised International Prognostic Scoring System (IPSS-R) categorization as low or intermediate-1 risk of progression</li> <li>Member has transfusion burden of 4 or more red blood cell (RBC) units within an 8-week period over the last 4 months</li> <li>Prescriber attestation that complete blood cell count (CBC) will be obtained prior to initiation, weekly for first two cycles, and prior to each cycle thereafter</li> <li>Member's weight has been provided with request</li> <li>Medication is prescribed at an FDA approved dose</li> </ul> |
| Revision/ Review<br>Date: 11/2024 | <ul> <li>Re-Authorization:</li> <li>Documentation or provider attestation of reduction in RBC transfusion burden as compared with baseline</li> <li>Provider attestation that patient is tolerating the medication and is not experiencing any serious adverse reactions</li> <li>Member's weight has been provided with request</li> <li>Medication is prescribed at an FDA approved dose</li> <li>If all of the above criteria are not met, the request is referred to a Medical Director/Clinical Reviewer for medical necessity review.</li> </ul>   |